Australia markets open in 5 hours 18 minutes
  • ALL ORDS

    7,282.10
    -45.90 (-0.63%)
     
  • AUD/USD

    0.7711
    -0.0046 (-0.60%)
     
  • ASX 200

    7,017.80
    -47.80 (-0.68%)
     
  • OIL

    62.61
    -0.77 (-1.21%)
     
  • GOLD

    1,778.00
    +7.40 (+0.42%)
     
  • BTC-AUD

    72,765.38
    +456.85 (+0.63%)
     
  • CMC Crypto 200

    1,278.33
    +43.91 (+3.56%)
     

AeroPress, Inc. Announces Winner of $100,000 Cookies for Kids’ Cancer Innovative Translational Research Award

AeroPress, Inc.
·6-min read

Inaugural Grant Funds Cutting-Edge Brain Tumor Research

Palo Alto, CA - Dr. Nicholas Vitanza (center) of Seattle Children's Research Institute is the winner of the $100,000 inaugural Innovative Translational Research Award underwritten by AeroPress, Inc. and administered by Cookies for Kids' Cancer. Dr. Vitanza and his fellow lab founders, Senior Research Technician Carrie Myers (left) and Senior Research Scientist Matt Biery (right), are pictured here with an award certificate prize pack including an AeroPress coffee maker and fresh-baked cookies from Cookies for Kids' Cancer. Dr. Vitanza is a pediatric neuro-oncologist at Seattle Children’s researching midline gliomas, a particularly aggressive form of brain tumor. His hope is to develop an immunotherapy with chimeric antigen receptor T cells to treat children who typically have a survival of only 11 months after diagnosis.
Palo Alto, CA - Dr. Nicholas Vitanza (center) of Seattle Children's Research Institute is the winner of the $100,000 inaugural Innovative Translational Research Award underwritten by AeroPress, Inc. and administered by Cookies for Kids' Cancer. Dr. Vitanza and his fellow lab founders, Senior Research Technician Carrie Myers (left) and Senior Research Scientist Matt Biery (right), are pictured here with an award certificate prize pack including an AeroPress coffee maker and fresh-baked cookies from Cookies for Kids' Cancer. Dr. Vitanza is a pediatric neuro-oncologist at Seattle Children’s researching midline gliomas, a particularly aggressive form of brain tumor. His hope is to develop an immunotherapy with chimeric antigen receptor T cells to treat children who typically have a survival of only 11 months after diagnosis.
Palo Alto, CA - Dr. Nicholas Vitanza (center) of Seattle Children's Research Institute is the winner of the $100,000 inaugural Innovative Translational Research Award underwritten by AeroPress, Inc. and administered by Cookies for Kids' Cancer. Dr. Vitanza and his fellow lab founders, Senior Research Technician Carrie Myers (left) and Senior Research Scientist Matt Biery (right), are pictured here with an award certificate prize pack including an AeroPress coffee maker and fresh-baked cookies from Cookies for Kids' Cancer. Dr. Vitanza is a pediatric neuro-oncologist at Seattle Children’s researching midline gliomas, a particularly aggressive form of brain tumor. His hope is to develop an immunotherapy with chimeric antigen receptor T cells to treat children who typically have a survival of only 11 months after diagnosis.

Palo Alto, California, March 01, 2021 (GLOBE NEWSWIRE) -- AeroPress, Inc., based in Palo Alto, California, announces the winner of the inaugural $100,000 Innovative Translational Research Award to a leading pediatric cancer researcher. The winner, Dr. Nicholas Vitanza from Seattle Children’s Research Institute, is focused on studying pediatric brain tumors. His winning project went through a rigorous peer-reviewed process consisting of top pediatric cancer researchers from leading hospitals across the country. Dr. Vitanza’s project was selected from proposals submitted by esteemed hospitals including St. Jude, Children’s Hospital of Philadelphia, Texas Children’s Cancer Center, Dana-Farber, and Memorial Sloan Kettering Cancer Center.

AeroPress, Inc. is underwriting the Innovative Translational Research Award. Founder and President Alan Adler says funding the award is a natural fit for his company, whose AeroPress designs are a new approach to coffee brewing. "When I first learned about Cookies for Kids’ Cancer from the founders, I knew instantly that I wanted to support ‘Cookies’ with all my heart," says Adler. "The more I learned about their program, the more enthusiastic I became. Their focus is on supporting research that has the best chance of helping children in the shortest time possible. That's exactly where I think the focus should be."

The grant is being administered by Cookies for Kids’ Cancer, a national pediatric cancer nonprofit that has funded more than $17 million for research into new, improved and less toxic pediatric cancer therapies. The organization encourages people to “be good cookies” by getting involved in whatever way motivates them to support pediatric cancer research. There have been nearly 14,000 grassroots events held in all 50 states and 20 countries by people of all ages. Said Cookies for Kids’ Cancer co-founder Gretchen Witt, “We are grateful to have support from AeroPress and are thrilled to have been able to create this award specifically for them. Researchers like Dr. Vitanza rely on support from private foundations like ours which is a vital part of their funding. On average it takes more than two years for a researcher to receive funding after submitting a grant request to the National Cancer Institute for review. That timeline for a project submitted to Cookies for Kids’ Cancer is around 60 days. And, when you’re a child battling cancer, days count.”

Dr. Nicholas Vitanza is a pediatric neuro-oncologist at Seattle Children’s researching midline gliomas (DMGs), a particularly aggressive form of brain tumor. His hope is to develop an immunotherapy with chimeric antigen receptor T cells to treat children who typically have a survival of only 11 months after diagnosis. "It is an honor to be awarded this award that will play a pivotal role in supporting our work,” said Vitanza. "Pediatric cancer continues to be dramatically underfunded compared to adult cancers at every level from National Institutes of Health funding to private sector support, so these awards are critical and literally make the research we conduct possible. DMG is responsible for an unimaginable 25,000 potential years of life lost every year just in the United States and we owe it to these children and their families to investigate new technologies as quickly and safely as possible and to also understand how best to deliver them.”

Pediatric cancer is the number one cause of death by disease of children in the United States under the age of 18. The types of cancers that children develop are different from adult cancers and, therefore, require specialized research. Two thirds of children treated for cancer develop long-term side effects as a result of their treatment, making improved, less toxic cancer treatments for children a critical research priority. "The lack of funding directed towards pediatric cancer astounds me as much today as the day my son Liam was diagnosed. It just doesn’t make sense to me that we invest so little money into a disease that preys on our most precious resource, our children,” said Witt. “To have an innovative company like AeroPress not only recognize the need but step up to the plate to fund a grant specific for new thinking by young investigators is truly amazing. My son was fascinated by science and figuring out how things work. He not only would have loved to know the inspiration behind AeroPress but would have cheered them on for their forward thinking by funding a grant specifically for the next generation."

For more information about this award and the winner, please visit https://aeropress.com/cookies-for-kids-cancer-award/.

About Cookies for Kids’ Cancer

Through the concept of local fundraising events and online cookie sales, Cookies for Kids’ Cancer has granted more than $17 million to date, funding nearly 100 research projects that have resulted in 25 treatments available to children today. The organization inspires individuals, organizations, and businesses to join in the fight against pediatric cancer by raising the funds for new, improved and less toxic treatments. Since Cookies for Kids’ Cancer launched in 2008, there have been more than 13,000 events in all 50 states and 20 countries. Grants are peer reviewed by a scientific advisory board of esteemed pediatric cancer oncologists, with funds going directly to the leading pediatric cancer institutions in the country including: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Children’s Hospital of Philadelphia, St. Jude Children’s Research Hospital, Fred Hutchinson Cancer Research Center, University of California San Francisco, and Texas Children’s Cancer Center. In addition, Cookies for Kids’ Cancer is the largest single donor to the Children’s Oncology Group Pediatric Early Phase – Clinical Trial Network (PEP-CTN) program which administers phase 1 treatments to children at 20 hospitals across the country – and matches what the Federal Government allocates per child enrolled. The organization has been profiled in the Wall Street Journal, Today Show, Good Morning America, NY Daily News, Family Circle Magazine and dozens of other local and national media outlets. In addition, the organization has received several national awards for its work. For more information, please visit www.cookiesforkidscancer.org.

About AeroPress, Inc.

AeroPress, Inc. is the manufacturer of the innovative AeroPress coffee maker and the new AeroPress Go travel coffee press. AeroPress products are a new approach to coffee brewing that makes it easy for anyone to brew rich, delicious coffee. For more information, please visit www.aeropress.com.

Attachment

CONTACT: Constance Romero AeroPress, Inc. 650-493-3050 constance@aeropress.com